Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
Mallinckrodt
Colorcon
McKesson
AstraZeneca

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

SMOFLIPID 20% Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for SMOFLIPID 20%
Drug patent expirations by year for SMOFLIPID 20%
Generic Entry Opportunity Date for SMOFLIPID 20%
Generic Entry Date for SMOFLIPID 20%*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
EMULSION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SMOFLIPID 20%

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fresenius KabiPhase 4
Fresenius KabiPhase 1/Phase 2
Mayo ClinicPhase 4

See all SMOFLIPID 20% clinical trials

Pharmacology for SMOFLIPID 20%
Drug ClassLipid Emulsion

US Patents and Regulatory Information for SMOFLIPID 20%

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa SMOFLIPID 20% fish oil; medium chain triglycerides; olive oil; soybean oil EMULSION;INTRAVENOUS 207648-001 Jul 13, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa SMOFLIPID 20% fish oil; medium chain triglycerides; olive oil; soybean oil EMULSION;INTRAVENOUS 207648-004 Aug 10, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa SMOFLIPID 20% fish oil; medium chain triglycerides; olive oil; soybean oil EMULSION;INTRAVENOUS 207648-002 Jul 13, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Fresenius Kabi Usa SMOFLIPID 20% fish oil; medium chain triglycerides; olive oil; soybean oil EMULSION;INTRAVENOUS 207648-003 Jul 13, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Express Scripts
Mallinckrodt
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.